+

RU2006113366A - Терапевтическое лечение - Google Patents

Терапевтическое лечение Download PDF

Info

Publication number
RU2006113366A
RU2006113366A RU2006113366/15A RU2006113366A RU2006113366A RU 2006113366 A RU2006113366 A RU 2006113366A RU 2006113366/15 A RU2006113366/15 A RU 2006113366/15A RU 2006113366 A RU2006113366 A RU 2006113366A RU 2006113366 A RU2006113366 A RU 2006113366A
Authority
RU
Russia
Prior art keywords
combination according
prevention
atherosclerosis
treatment
pharmaceutically acceptable
Prior art date
Application number
RU2006113366/15A
Other languages
English (en)
Other versions
RU2358737C2 (ru
Inventor
Джей Лал МЕХТА (US)
Джей Лал МЕХТА
Original Assignee
АстраЗенека Ю-Кей Лимитед (GB)
АстраЗенека Ю-Кей Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by АстраЗенека Ю-Кей Лимитед (GB), АстраЗенека Ю-Кей Лимитед filed Critical АстраЗенека Ю-Кей Лимитед (GB)
Publication of RU2006113366A publication Critical patent/RU2006113366A/ru
Application granted granted Critical
Publication of RU2358737C2 publication Critical patent/RU2358737C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)

Claims (11)

1. Комбинация, содержащая кандесартан или его фармацевтически приемлемую соль и розувастатин или его фармацевтически приемлемую соль, для предупреждения или лечения атеросклероза.
2. Фармацевтическая композиция, содержащая комбинацию по п.1 вместе с фармацевтически приемлемым разбавителем или носителем, для применения в предупреждении или лечении атеросклероза.
3. Фармацевтическая композиция, содержащая комбинацию по п.1 вместе с фармацевтически приемлемым разбавителем или носителем, для применения в предупреждении сердечно-сосудистых событий.
4. Комбинация по п.1 для применения в изготовлении лекарства для предупреждения или лечения атеросклероза.
5. Комбинация по п.1 для применения в изготовлении лекарства для предупреждения сердечно-сосудистых событий.
6. Комбинация по п.1 для применения в качестве лекарственного средства для предупреждения или лечения атеросклероза.
7. Комбинация по п.1 для применения в качестве лекарственного средства для предупреждения сердечно-сосудистых событий.
8. Способ предупреждения или лечения атеросклероза у теплокровного животного, например человека, включающий введение комбинации по п.1.
9. Способ предупреждения сердечно-сосудистых событий у теплокровного животного, например человека, включающий введение комбинации по п.1.
10. Набор, включающий комбинацию по п.1, возможно, с инструкциями по применению в предупреждении или лечении атеросклероза.
11. Комбинация по п.1, в которой кандесартан находится в форме кандесартана цилексетила.
RU2006113366/15A 2003-09-26 2004-09-22 Терапевтическое лечение RU2358737C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0322552.1 2003-09-26
GBGB0322552.1A GB0322552D0 (en) 2003-09-26 2003-09-26 Therapeutic treatment

Publications (2)

Publication Number Publication Date
RU2006113366A true RU2006113366A (ru) 2007-11-10
RU2358737C2 RU2358737C2 (ru) 2009-06-20

Family

ID=29286881

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006113366/15A RU2358737C2 (ru) 2003-09-26 2004-09-22 Терапевтическое лечение

Country Status (29)

Country Link
US (2) US7932263B2 (ru)
EP (1) EP1673091B1 (ru)
JP (1) JP4841433B2 (ru)
KR (1) KR101129767B1 (ru)
CN (1) CN100515421C (ru)
AT (1) ATE451103T1 (ru)
AU (1) AU2004275567B2 (ru)
BR (1) BRPI0414724A (ru)
CA (1) CA2540102C (ru)
CY (1) CY1109814T1 (ru)
DE (1) DE602004024555D1 (ru)
DK (1) DK1673091T3 (ru)
ES (1) ES2336450T3 (ru)
GB (1) GB0322552D0 (ru)
HK (1) HK1090553A1 (ru)
HR (1) HRP20100080T1 (ru)
IL (1) IL174536A (ru)
IS (1) IS2729B (ru)
MX (1) MXPA06003353A (ru)
NO (1) NO335813B1 (ru)
NZ (1) NZ546162A (ru)
PL (1) PL1673091T3 (ru)
PT (1) PT1673091E (ru)
RU (1) RU2358737C2 (ru)
SG (1) SG145773A1 (ru)
SI (1) SI1673091T1 (ru)
UA (1) UA90249C2 (ru)
WO (1) WO2005030215A2 (ru)
ZA (1) ZA200602433B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
WO2007051007A2 (en) * 2005-10-28 2007-05-03 Novartis Ag Combination of antihypertensives with cholesterol-lowering agent
EP2483401B1 (en) * 2009-09-29 2017-06-21 Butamax (TM) Advanced Biofuels LLC Improved yeast production host cells
US20120239131A1 (en) * 2011-03-15 2012-09-20 Medtronic Vascular, Inc. Methods and apparatus for treatment of aneurysmal tissue
ES2622893T3 (es) * 2011-12-09 2017-07-07 Tratamiento de la pared arterial mediante la combinación de un inhibidor del SRAA y un inhibidor de la HMG-CoA reductasa
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
KR101771766B1 (ko) 2013-12-30 2017-08-28 알보젠코리아 주식회사 안지오텐신-Ⅱ 수용체 차단제 및 HMG-CoA 환원효소 저해제를 포함하는 약제학적 복합제제
CN109996545A (zh) * 2016-11-15 2019-07-09 株式会社Lg化学 用于治疗2型糖尿病和糖尿病性血脂异常的药物复合物

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) * 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) * 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
CA2125251C (en) 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
JP3883205B2 (ja) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド アンギオテンシン▲ii▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
EP0914158B2 (en) 1996-04-05 2006-01-25 Takeda Chemical Industries, Ltd. Pharmaceutical combination containing a compound having angiotensin ii antagonistic activity and a compound which increases the insulin-sensitivity
ES2232873T3 (es) * 1996-07-15 2005-06-01 Sankyo Company Limited Composiciones farmaceuticas que comprenden el cs-866 y otros agentes que mejoran la resistencia a la insulina y su uso para el tratamiento de la arterosclerosis y el xantoma.
JPH1081633A (ja) 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
AP1207A (en) 1997-08-29 2003-09-20 Pfizer Prod Inc Combination therapy.
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
GB9900339D0 (en) 1999-01-09 1999-02-24 Zeneca Ltd Chemical compounds
AR022462A1 (es) 1999-02-06 2002-09-04 Astrazeneca Uk Ltd Uso de un agente que disminuye el colesterol
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN1353706A (zh) 1999-04-13 2002-06-12 巴斯福股份公司 整合素受体配体
UA77151C2 (en) 1999-08-30 2006-11-15 Sanofi Aventis Deutschland Use of ramipril for prevention of cardiovascular events
CA2381926A1 (en) 1999-08-31 2001-03-08 Brigham And Women's Hospital, Inc. Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AR030414A1 (es) 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SK14642002A3 (sk) * 2000-04-12 2003-05-02 Novartis Ag Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor
US6620821B2 (en) * 2000-06-15 2003-09-16 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
JP2002145770A (ja) * 2000-08-30 2002-05-22 Sankyo Co Ltd 心不全の予防又は治療のための医薬組成物
CA2420844A1 (en) 2000-08-30 2003-02-28 Sankyo Company, Limited Medicinal compositions for preventing or treating heart failure
GB0028429D0 (en) 2000-11-22 2001-01-10 Astrazeneca Ab Therapy
ATE331512T1 (de) * 2001-01-26 2006-07-15 Schering Corp Verwendung azetidinone-substituierter verbindungen zur behandlung der sitosterolhämie
NZ545332A (en) * 2001-01-26 2007-09-28 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
WO2002095402A2 (en) * 2001-04-18 2002-11-28 Mcgill University Individualization of therapy with hyperlipidemia agents
SE0103509D0 (sv) 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
ATE433978T1 (de) * 2003-04-29 2009-07-15 Pfizer Ltd 5,7-diaminopyrazolo 4,3-d pyrimidine zur verwendung in der behandlung von bluthochdruck
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
JP2005126338A (ja) 2003-10-21 2005-05-19 Boehringer Ingelheim Pharma Gmbh & Co Kg 心不全治療剤
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
US20060078615A1 (en) 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin

Also Published As

Publication number Publication date
UA90249C2 (ru) 2010-04-26
ES2336450T3 (es) 2010-04-13
DE602004024555D1 (de) 2010-01-21
SG145773A1 (en) 2008-09-29
JP4841433B2 (ja) 2011-12-21
GB0322552D0 (en) 2003-10-29
KR20060108623A (ko) 2006-10-18
NO335813B1 (no) 2015-02-23
IS2729B (is) 2011-04-15
NZ546162A (en) 2008-11-28
EP1673091B1 (en) 2009-12-09
ATE451103T1 (de) 2009-12-15
US20110046119A1 (en) 2011-02-24
HK1090553A1 (en) 2006-12-29
IL174536A (en) 2010-12-30
BRPI0414724A (pt) 2006-11-21
WO2005030215A3 (en) 2005-06-02
AU2004275567B2 (en) 2008-01-10
DK1673091T3 (da) 2010-03-22
JP2007506720A (ja) 2007-03-22
NO20061744L (no) 2006-06-22
PL1673091T3 (pl) 2010-04-30
US20070275989A1 (en) 2007-11-29
RU2358737C2 (ru) 2009-06-20
EP1673091A2 (en) 2006-06-28
WO2005030215A2 (en) 2005-04-07
KR101129767B1 (ko) 2012-03-26
HRP20100080T1 (hr) 2010-04-30
CA2540102C (en) 2012-07-24
CN1886136A (zh) 2006-12-27
IL174536A0 (en) 2008-04-13
IS8421A (is) 2006-04-21
US7932263B2 (en) 2011-04-26
PT1673091E (pt) 2010-02-15
MXPA06003353A (es) 2006-06-08
SI1673091T1 (sl) 2010-03-31
CA2540102A1 (en) 2005-04-07
CY1109814T1 (el) 2014-09-10
ZA200602433B (en) 2007-06-27
CN100515421C (zh) 2009-07-22
AU2004275567A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
IL171977A (en) Cyclic sulfonamide for inhibition of gamma-secretase, process for its preparation and a pharmaceutical composition comprising the same
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
CZ309247B6 (cs) 40-O-(2-hydroxyethyl)rapamycin pro použití jako jediná účinná látka při léčení solidního nádoru
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
TNSN06034A1 (en) Pyridazine derivatives and their use as therapeutic agents
RU2006113366A (ru) Терапевтическое лечение
EA200800880A1 (ru) Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции
SE0401342D0 (sv) Therapeutic compounds
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
GB0130677D0 (en) Medicaments and novel compounds
NO20054714L (no) Fremgangsmate for behandling av svake kognitive svekkelser, og for a forhindre eller utsette Alzheimers sykdom
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
EA200801305A1 (ru) Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии
PT1656131E (pt) Utilização de betaína para tratar claudicação intermitente
HK1077215A1 (en) A pharmaceutical composition for treatment of acute myocardial infarction
GEP201606538B (en) Preoperative treatment of post operative pain
RU2005131578A (ru) Аплидин для лечения множественной миеломы
DE60204694D1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
ATE404192T1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
HUP0401798A2 (hu) Rosuvastatin alkalmazása demencia előtti állapotokban használható gyógyszerkészítmény előállítására
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof
AR047154A1 (es) Tratamiento del insomnio en pacientes humanos administrandoles una cantidad diaria de gaboxadol
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160923

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载